JPH02502122A - 液体中のリガンドを検出及び定量する方法 - Google Patents

液体中のリガンドを検出及び定量する方法

Info

Publication number: JPH02502122A
Authority: JP; Japan
Prior art keywords: biotin; ligand; labeled; question; avidin
Prior art date: 1987-01-15
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP63501878A

Other languages

English (en)

Japanese (ja)

Inventor

ヘベイ，リチヤード・シー

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-01-15

Filing date

1988-01-14

Publication date

1990-07-12

1987-02-11 Priority claimed from US07/013,581 external-priority patent/US4863876A/en

1988-01-14 Application filed by Individual filed Critical Individual

1990-07-12 Publication of JPH02502122A publication Critical patent/JPH02502122A/ja

Status Pending legal-status Critical Current

Links

239000003446 ligand Substances 0.000 title claims description 217
239000007788 liquid Substances 0.000 title claims description 205
238000000034 method Methods 0.000 title claims description 191
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 502
239000011616 biotin Substances 0.000 claims description 271
229960002685 biotin Drugs 0.000 claims description 271
235000020958 biotin Nutrition 0.000 claims description 251
238000002875 fluorescence polarization Methods 0.000 claims description 206
108090001008 Avidin Proteins 0.000 claims description 186
230000009870 specific binding Effects 0.000 claims description 135
239000000427 antigen Substances 0.000 claims description 115
238000009739 binding Methods 0.000 claims description 112
102000036639 antigens Human genes 0.000 claims description 98
108091007433 antigens Proteins 0.000 claims description 98
230000027455 binding Effects 0.000 claims description 93
238000011534 incubation Methods 0.000 claims description 57
230000010287 polarization Effects 0.000 claims description 56
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 22
238000005259 measurement Methods 0.000 claims description 22
239000011230 binding agent Substances 0.000 claims description 3
238000000691 measurement method Methods 0.000 claims description 3
230000001568 sexual effect Effects 0.000 claims description 3
238000002156 mixing Methods 0.000 claims description 2
238000010791 quenching Methods 0.000 claims 2
230000000171 quenching effect Effects 0.000 claims 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
229910052739 hydrogen Inorganic materials 0.000 claims 1
239000001257 hydrogen Substances 0.000 claims 1
239000012071 phase Substances 0.000 description 98
239000003292 glue Substances 0.000 description 82
238000003556 assay Methods 0.000 description 54
239000000523 sample Substances 0.000 description 29
238000007792 addition Methods 0.000 description 25
239000000243 solution Substances 0.000 description 24
238000006243 chemical reaction Methods 0.000 description 21
239000000126 substance Substances 0.000 description 21
239000003153 chemical reaction reagent Substances 0.000 description 17
230000001745 anti-biotin effect Effects 0.000 description 16
239000000047 product Substances 0.000 description 15
238000003018 immunoassay Methods 0.000 description 14
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
230000035945 sensitivity Effects 0.000 description 12
241000283973 Oryctolagus cuniculus Species 0.000 description 11
239000000203 mixture Substances 0.000 description 10
150000003384 small molecules Chemical class 0.000 description 10
108020004414 DNA Proteins 0.000 description 8
239000000853 adhesive Substances 0.000 description 8
230000001070 adhesive effect Effects 0.000 description 8
239000000872 buffer Substances 0.000 description 8
150000001875 compounds Chemical class 0.000 description 8
230000005284 excitation Effects 0.000 description 8
239000012085 test solution Substances 0.000 description 8
230000000694 effects Effects 0.000 description 7
239000007790 solid phase Substances 0.000 description 7
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
230000007423 decrease Effects 0.000 description 6
239000004615 ingredient Substances 0.000 description 6
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
102000004169 proteins and genes Human genes 0.000 description 6
108090000623 proteins and genes Proteins 0.000 description 6
239000012491 analyte Substances 0.000 description 5
238000001514 detection method Methods 0.000 description 5
238000002372 labelling Methods 0.000 description 5
230000036963 noncompetitive effect Effects 0.000 description 5
238000000926 separation method Methods 0.000 description 5
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
239000011324 bead Substances 0.000 description 4
230000009137 competitive binding Effects 0.000 description 4
230000001965 increasing effect Effects 0.000 description 4
239000008363 phosphate buffer Substances 0.000 description 4
230000005855 radiation Effects 0.000 description 4
-1 tradiol Chemical compound 0.000 description 4
AYXZIZMZXAORLO-UFLZEWODSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoic acid;1-hydroxypyrrolidine-2,5-dione Chemical compound ON1C(=O)CCC1=O.N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 AYXZIZMZXAORLO-UFLZEWODSA-N 0.000 description 3
241000283707 Capra Species 0.000 description 3
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 3
102000004877 Insulin Human genes 0.000 description 3
108090001061 Insulin Proteins 0.000 description 3
239000000020 Nitrocellulose Substances 0.000 description 3
238000010586 diagram Methods 0.000 description 3
239000012530 fluid Substances 0.000 description 3
230000005283 ground state Effects 0.000 description 3
229940125396 insulin Drugs 0.000 description 3
229920002521 macromolecule Polymers 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
239000000463 material Substances 0.000 description 3
230000028161 membrane depolarization Effects 0.000 description 3
229920001220 nitrocellulos Polymers 0.000 description 3
239000011541 reaction mixture Substances 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000002904 solvent Substances 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
238000012360 testing method Methods 0.000 description 3
CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 2
QNFBKOHHLAWWTC-UHFFFAOYSA-N Fraxidin Chemical compound C1=CC(=O)OC2=C1C=C(OC)C(OC)=C2O QNFBKOHHLAWWTC-UHFFFAOYSA-N 0.000 description 2
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
ATHHXGZTWNVVOU-UHFFFAOYSA-N N-methylformamide Chemical compound CNC=O ATHHXGZTWNVVOU-UHFFFAOYSA-N 0.000 description 2
239000004677 Nylon Substances 0.000 description 2
239000004793 Polystyrene Substances 0.000 description 2
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
230000002860 competitive effect Effects 0.000 description 2
230000009918 complex formation Effects 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
239000000975 dye Substances 0.000 description 2
229960003399 estrone Drugs 0.000 description 2
230000007717 exclusion Effects 0.000 description 2
239000007850 fluorescent dye Substances 0.000 description 2
OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
239000011521 glass Substances 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
239000005556 hormone Substances 0.000 description 2
150000002605 large molecules Chemical class 0.000 description 2
239000007791 liquid phase Substances 0.000 description 2
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
150000007523 nucleic acids Chemical class 0.000 description 2
239000002773 nucleotide Substances 0.000 description 2
125000003729 nucleotide group Chemical group 0.000 description 2
229920001778 nylon Polymers 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
229920002223 polystyrene Polymers 0.000 description 2
239000011148 porous material Substances 0.000 description 2
150000004032 porphyrins Chemical class 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
238000012545 processing Methods 0.000 description 2
238000011002 quantification Methods 0.000 description 2
230000002285 radioactive effect Effects 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
201000005404 rubella Diseases 0.000 description 2
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
239000000741 silica gel Substances 0.000 description 2
229910002027 silica gel Inorganic materials 0.000 description 2
150000003431 steroids Chemical class 0.000 description 2
210000002784 stomach Anatomy 0.000 description 2
238000013519 translation Methods 0.000 description 2
ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 2
HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 2
DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
VWLAGVVQCMHHJW-UHFFFAOYSA-N 1-(2-aminoethyl)-3-(3',6'-dihydroxy-3-oxospiro[2-benzofuran-1,9'-xanthene]-5-yl)thiourea Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C21OC(=O)C1=CC(NC(=S)NCCN)=CC=C21 VWLAGVVQCMHHJW-UHFFFAOYSA-N 0.000 description 1
VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical compound CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 1
102000015427 Angiotensins Human genes 0.000 description 1
108010064733 Angiotensins Proteins 0.000 description 1
241000218645 Cedrus Species 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
229920013685 Estron Polymers 0.000 description 1
102000004641 Fetal Proteins Human genes 0.000 description 1
108010003471 Fetal Proteins Proteins 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
241000322338 Loeseliastrum Species 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
101000921279 Mus musculus EMILIN-2 Proteins 0.000 description 1
OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
YWYQTGBBEZQBGO-BERLURQNSA-N Pregnanediol Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](O)C)[C@@]2(C)CC1 YWYQTGBBEZQBGO-BERLURQNSA-N 0.000 description 1
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Natural products C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
YWYQTGBBEZQBGO-UHFFFAOYSA-N UC1011 Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(O)C)C1(C)CC2 YWYQTGBBEZQBGO-UHFFFAOYSA-N 0.000 description 1
241000700605 Viruses Species 0.000 description 1
208000009956 adenocarcinoma Diseases 0.000 description 1
210000004381 amniotic fluid Anatomy 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000003172 anti-dna Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000003809 bile pigment Chemical class 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
102000023732 binding proteins Human genes 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000008033 biological extinction Effects 0.000 description 1
239000013060 biological fluid Substances 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
230000006287 biotinylation Effects 0.000 description 1
238000007413 biotinylation Methods 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
IAQRGUVFOMOMEM-UHFFFAOYSA-N butene Natural products CC=CC IAQRGUVFOMOMEM-UHFFFAOYSA-N 0.000 description 1
DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000004737 colorimetric analysis Methods 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
229960005156 digoxin Drugs 0.000 description 1
LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
239000003480 eluent Substances 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
229960000304 folic acid Drugs 0.000 description 1
235000019152 folic acid Nutrition 0.000 description 1
239000011724 folic acid Substances 0.000 description 1
230000002949 hemolytic effect Effects 0.000 description 1
229960001340 histamine Drugs 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
150000002540 isothiocyanates Chemical class 0.000 description 1
201000007270 liver cancer Diseases 0.000 description 1
208000014018 liver neoplasm Diseases 0.000 description 1
MBABOKRGFJTBAE-UHFFFAOYSA-N methyl methanesulfonate Chemical compound COS(C)(=O)=O MBABOKRGFJTBAE-UHFFFAOYSA-N 0.000 description 1
229960005181 morphine Drugs 0.000 description 1
229960002748 norepinephrine Drugs 0.000 description 1
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
239000002245 particle Substances 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
238000005498 polishing Methods 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
238000004313 potentiometry Methods 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
239000000186 progesterone Substances 0.000 description 1
229960003387 progesterone Drugs 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
239000012521 purified sample Substances 0.000 description 1
150000003222 pyridines Chemical class 0.000 description 1
238000012207 quantitative assay Methods 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
238000007788 roughening Methods 0.000 description 1
239000012723 sample buffer Substances 0.000 description 1
229940076279 serotonin Drugs 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
241000894007 species Species 0.000 description 1
238000002798 spectrophotometry method Methods 0.000 description 1
239000013589 supplement Substances 0.000 description 1
208000006379 syphilis Diseases 0.000 description 1
229960003604 testosterone Drugs 0.000 description 1
229940034208 thyroxine Drugs 0.000 description 1
XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
238000005406 washing Methods 0.000 description 1
229910052724 xenon Inorganic materials 0.000 description 1
FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Biotechnology (AREA)
Analytical Chemistry (AREA)
Cell Biology (AREA)
Pathology (AREA)
Food Science & Technology (AREA)
Medicinal Chemistry (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
General Physics & Mathematics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Investigating Or Analysing Biological Materials (AREA)
Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)

JP63501878A 1987-01-15 1988-01-14 液体中のリガンドを検出及び定量する方法 Pending JPH02502122A (ja)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
US360487A	1987-01-15	1987-01-15
US356687A	1987-01-15	1987-01-15
US003,604		1987-01-15
US003,566		1987-01-15
US07/013,581 US4863876A (en)	1987-01-15	1987-02-11	Method of detecting and quantifying ligands in liquids via biotin-avidin-medicated fluorescence polarization
US013,581		1987-02-11

Publications (1)

Publication Number	Publication Date
JPH02502122A true JPH02502122A (ja)	1990-07-12

Family

ID=27357435

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP63501878A Pending JPH02502122A (ja)	1987-01-15	1988-01-14	液体中のリガンドを検出及び定量する方法

Country Status (4)

Country	Link
JP (1)	JPH02502122A (fr)
AU (1)	AU1342488A (fr)
CA (1)	CA1297406C (fr)
WO (1)	WO1988005538A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2003031974A1 (fr) *	2001-09-19	2003-04-17	Daiichi Pure Chemicals Co., Ltd.	Polymere luminescent utilisable dans des bioessais
JP2018522214A (ja) *	2015-05-11	2018-08-09	アクセスメディカルシステムズ，リミティド	イムノアッセイにおける試験プローブおよび試薬の再利用方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IE64286B1 (en) *	1988-05-25	1995-07-26	Boehringer Mannheim Gmbh	Process for the determination of an immunologically detectable substance and a suitable vessel therefor
DE3834766A1 (de) *	1988-10-12	1990-04-26	Boehringer Mannheim Gmbh	Verfahren zur bestimmung einer spezifisch bindefaehigen substanz
GB8902689D0 (en) *	1989-02-07	1989-03-30	Ici Plc	Assay method
US6087188A (en) *	1992-11-13	2000-07-11	Alk A/S	Two-site immunoassay for an antibody with chemiluminescent label and biotin bound ligand
US6503709B1 (en)	1997-07-03	2003-01-07	Id Biomedical Corporation	Methods for rapidly detecting methicillin resistant staphylococci

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0201211A1 (fr) *	1985-04-10	1986-11-12	Whittaker Corporation	Méthode et compositions pour immuno-essais visuels à phase solide basés sur des particules microsphériques et luminescente

1988
- 1988-01-14 JP JP63501878A patent/JPH02502122A/ja active Pending
- 1988-01-14 AU AU13424/88A patent/AU1342488A/en not_active Abandoned
- 1988-01-14 WO PCT/US1988/000067 patent/WO1988005538A1/fr not_active Ceased
- 1988-01-15 CA CA000556618A patent/CA1297406C/fr not_active Expired - Lifetime

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2003031974A1 (fr) *	2001-09-19	2003-04-17	Daiichi Pure Chemicals Co., Ltd.	Polymere luminescent utilisable dans des bioessais
US8183060B2 (en)	2001-09-19	2012-05-22	Daiichi Pure Chemicals Co., Ltd.	Luminescent polymer and use thereof in bioassay
JP2018522214A (ja) *	2015-05-11	2018-08-09	アクセスメディカルシステムズ，リミティド	イムノアッセイにおける試験プローブおよび試薬の再利用方法

Also Published As

Publication number	Publication date
WO1988005538A1 (fr)	1988-07-28
AU1342488A (en)	1988-08-10
CA1297406C (fr)	1992-03-17

Publication	Publication Date	Title
US4923819A (en)	1990-05-08	Time-resolved fluorescence immunoassay
US4822733A (en)	1989-04-18	Lifetime-resolved assay procedures
US6251581B1 (en)	2001-06-26	Assay method utilizing induced luminescence
FI92110C (fi)	1994-09-26	Useiden analyyttien vallitsevien konsentraatioiden määrittäminen
US4863876A (en)	1989-09-05	Method of detecting and quantifying ligands in liquids via biotin-avidin-medicated fluorescence polarization
US5464741A (en)	1995-11-07	Palladium (II) octaethylporphine alpha-isothiocyanate as a phosphorescent label for immunoassays
JP4163869B2 (ja)	2008-10-08	検出方法
JP7344928B2 (ja)	2023-09-14	ヘテロ環式化合物のバイオコンジュゲート
CN102892896A (zh)	2013-01-23	具有改进灵敏度的均相化学发光测试方法
US12416627B2 (en)	2025-09-16	Immunoassay with enhanced sensitivity
US4231750A (en)	1980-11-04	Methods for performing chemical assays using fluorescence and photon counting
CN110018307A (zh)	2019-07-16	一种光激化学发光检测仪及其使用方法
JPH06506058A (ja)	1994-07-07	分離方法
CN114324862A (zh)	2022-04-12	一种非洲猪瘟病毒均相检测反应试剂及检测方法
JP6545960B2 (ja)	2019-07-17	標的物質の検出用試薬、検出方法および標的物質を検出するために用いられる担体ならびにその製造方法
JPH02502122A (ja)	1990-07-12	液体中のリガンドを検出及び定量する方法
US20200209230A1 (en)	2020-07-02	Methods and compositions relating to small molecule analyte assays
CN102575156A (zh)	2012-07-11	检测中所用的颗粒中的信号生成的稳定化
JP2002503812A (ja)	2002-02-05	全アナライトの測定方法
Haasnoot et al.	2000	Immunochemical and receptor technologies
Rubenstein	1981	New Homogeneous Assay Methods for the Determination of Proteins
Diamandis et al.	1988	MC-1 A new generation of time-resolved fluoroimmunoassays with europium chelates as labels
CN115078712A (zh)	2022-09-20	一种碳量子点荧光淬灭免疫层析试纸条的制备及应用
Seare	1988	Immunoassay techniques
Ricchiuti	2010	IMMUNOASSAY-BASED TECHNOL-OGIES FOR THE MEASUREMENT OF BIOLOGICAL MATERIALS USED FOR BIOMARKERS DISCOVERY